Computer aided identification of small molecules disrupting uPAR/α5b1-integrin interaction: A new paradigm for metastasis prevention

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Chaurasia, Pratima ^a   Mezei, Mihaly ^a   Zhou, Ming Ming ^a   Ossowski, Liliana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (PYRIDIN 2 YLAMINO)QUINOLIN 8 OL; 2,2' (METHYLIMINO)DI (8 QUINOLINOL); MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; HEAD AND NECK CARCINOMA; METASTASIS INHIBITION; MOLECULAR DOCKING; PROTEIN PROTEIN INTERACTION;

EID: 84864289379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004617     Document Type: Article

References (33)

1. Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. APMIS 116(7-8): 754-770.
2. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63(7): 1684-1695.
3. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147(1): 89-104.
4. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1(5): 445-457.
5. Chaurasia P, et al. (2006) A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem 281(21): 14852-14863.
6. Llinas P, et al. (2005) Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 24(9): 1655-1663.
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3): 3-26.
8. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12(4): 863-879.
9. de Bock CE, Wang Y (2004) Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24(1): 13-39.
10. Duffy MJ, Duggan C (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37(7): 541-548.
11. Romer J, Nielsen BS, Ploug M (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 10(19): 2359-2376.
12. Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5(16): 1760-1771.
13. Mazar AP (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 14(18): 5649-5655.
14. Tang CH, Wei Y (2008) The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 65(12): 1916-1932.
15. Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, et al. (2005) Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 114(2): 291-298.
16. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, et al. (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A 103(46): 17361-17365.
17. Allgayer H, Aguirre-Ghiso JA (2008) The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116(7-8): 602-614.
18. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, et al. (2002) Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 20(8): 2005-2016.
19. Luque A, Gómez M, Puzon W, Takada Y, Sánchez-Madrid F, et al. (1996) Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem 271(19): 11067-11075.
20. Ossowski L (1988) Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52(3): 321-328.
21. Kim J, Yu W, Kovalski K, Ossowski L (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94(3): 353-362.
22. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, et al. (1996) Regulation of integrin function by the urokinase receptor. Science 273(5281): 1551-1555.
23. Petty HR, Worth RG, Todd RF 3rd (2002) Interactions of integrins with their partner proteins in leukocyte membranes. Immunol Res 25(1): 75-95.
24. Ossowski L, Aguirre-Ghiso JA (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12(5): 613-620.
25. Preissner KT, Kanse SM, May AE (2000) Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 12(5): 621-628.
26. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3(12): 932-943.
27. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N (2007) uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177(5): 927-939.
28. Mould AP, Humphries MJ (2004) Regulation of integrin function through conformational complexity: not simply a knee-jerk reaction? Curr Opin Cell Biol 16(5): 544-551.
29. Adair BD, Xiong JP, Maddock C, Goodman SL, Arnaout MA, et al. (2005) Three-dimensional EM structure of the ectodomain of integrin {alpha}V{-beta}3 in a complex with fibronectin. J Cell Biol 168(7): 1109-1118.
30. Lo Conte L, Chothia C, Janin J (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285(5): 2177-2198.
31. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3(4): 301-317.
32. Ossowski L, Reich E (1980) Experimental model for quantitative study of metastasis. Cancer Res 40(7): 2300-2309.
33. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64(20): 7336-7345.